Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 43 (3), 346-81

Enalapril. A Reappraisal of Its Pharmacology and Therapeutic Use in Hypertension


Enalapril. A Reappraisal of Its Pharmacology and Therapeutic Use in Hypertension

P A Todd et al. Drugs.


Enalapril, an angiotensin converting enzyme (ACE) inhibitor usually administered orally once daily, decreases blood pressure by lowering peripheral vascular resistance without increasing heart rate or output. It is effective in lowering blood pressure in all grades of essential and renovascular hypertension. Patients not responding adequately to enalapril monotherapy usually respond with the addition of a thiazide diuretic (or a calcium antagonist or beta-blocker), and rarely require a third antihypertensive agent. Enalapril is at least as effective as other established and newer ACE inhibitors, and members of other antihypertensive drug classes including diuretics, beta-blockers, calcium antagonists and alpha-blockers, but therapy with enalapril may be less frequently limited by serious adverse effects or treatment contraindications than with other drug classes. The most frequent adverse effect limiting all ACE inhibitor therapy in clinical practice is cough. This favourable profile of efficacy and tolerability, and the substantial weight of clinical experience, explain the increasing acceptance of enalapril as a major antihypertensive treatment and supports its use as logical first-line therapeutic option.

Similar articles

See all similar articles

Cited by 18 PubMed Central articles

See all "Cited by" articles


    1. J Urol. 1990 Jun;143(6):1237-8 - PubMed
    1. J Hum Hypertens. 1989 Jun;3 Suppl 1:153-8 - PubMed
    1. J Cardiovasc Pharmacol. 1987 Dec;10(6):723-7 - PubMed
    1. J Heart Lung Transplant. 1991 May-Jun;10(3):373-9 - PubMed
    1. J Am Board Fam Pract. 1989 Jul-Sep;2(3):172-90; discussion 190 - PubMed

MeSH terms

LinkOut - more resources